Stifel Financial Corp Cuts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Stifel Financial Corp reduced its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 6.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,536 shares of the company’s stock after selling 1,888 shares during the quarter. Stifel Financial Corp’s holdings in IDEAYA Biosciences were worth $872,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of IDYA. RA Capital Management L.P. purchased a new position in shares of IDEAYA Biosciences in the third quarter worth $42,681,000. Readystate Asset Management LP bought a new stake in IDEAYA Biosciences in the 3rd quarter worth about $520,000. RTW Investments LP purchased a new position in IDEAYA Biosciences in the 3rd quarter worth about $6,336,000. Janus Henderson Group PLC lifted its stake in IDEAYA Biosciences by 26.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock valued at $163,518,000 after acquiring an additional 1,086,356 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in shares of IDEAYA Biosciences during the 3rd quarter valued at about $213,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IDYA has been the topic of a number of research reports. Oppenheimer restated an “outperform” rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Stifel Nicolaus raised their price objective on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. Finally, Leerink Partners cut shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Trading Down 0.3 %

NASDAQ IDYA opened at $25.30 on Wednesday. IDEAYA Biosciences, Inc. has a 12 month low of $24.48 and a 12 month high of $47.74. The company’s 50-day moving average price is $28.17 and its 200-day moving average price is $33.84. The stock has a market cap of $2.19 billion, a PE ratio of -10.86 and a beta of 0.79.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same period in the previous year, the firm earned ($0.46) earnings per share. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.